Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Neil L Berinstein, Gail Klein, Katerina Welsh, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A Aljama, Jean-François Larouche

Blood (2022) 140 (Supplement 1): 9383–9384.

https://doi.org/10.1182/blood-2022-169245

Published: 2022

Journal Articles

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Nicholas Allen Forward, MDMSc,FRCPC, Pierre Laneuville, MD FRCPC, Joy Mangel, MD FRCPC, Douglas A. Stewart, MD FRCPC, Irina Amitai, MD, Gail Klein, MSc, Nancy Pennell, BSc, Iran Rashedi, MD MSc, Kim Roos, BA, BSc, Yogesh Bramhecha, Rebekah Conlon, RN

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-136751

Published: 2020

Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc

Blood (2019) 134 (Supplement_1): 3236.

https://doi.org/10.1182/blood-2019-125963

Published: 2019

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Anca Prica, MD, Ariella Pratzer, Matthew C Cheung, MD, Kim Thompson, Eugenia Piliotis, MD, Neil L Berinstein, MD, Kevin R. Imrie, MD, Rahim Pradhan, Anju Vyas, David Good, MD, Liying Zhang, PhD, Rena Buckstein, MD

Blood (2013) 122 (21): 5093.

https://doi.org/10.1182/blood.V122.21.5093.5093

Published: 2013

Journal Articles

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Neil L Berinstein, MD, FRCPC, Nancy M Pennell, B Sc, Mary-Anne Cussen, RN, BScN, CCRP, Kevin R Imrie, MD, Eugenia Piliotis, MD, FRCPC, Rena Buckstein, MD, Zeina Ghorab, MD, Ellen Anne Miles, MSc, Alden E. Chesney, MD, Matthew Cheung, MD

Blood (2012) 120 (21): 3681.

https://doi.org/10.1182/blood.V120.21.3681.3681

Published: 2012

Journal Articles

An Index of SNPs in Immune Genes May Enhance the Prognostic Value of IPI in Patients with Aggressive Non-Hodgkin's Lymphoma

Nancy M Pennell, B Sc, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2653.

https://doi.org/10.1182/blood.V118.21.2653.2653

Published: 2011

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

Journal Articles

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Lee Mozessohn, MD, Matthew Cheung, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC, Neil L Berinstein, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, John Kuruvilla, MD, FRCPC, Eugenia Piliotis, MD, FRCPC, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4981.

https://doi.org/10.1182/blood.V118.21.4981.4981

Published: 2011

Journal Articles

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD, Neil L Berinstein, MD, FRCPC, Nancy Pennell, BSc, Matthew Cheung, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, Violet Miliken, Marciano D. Reis, MD, FRCPC, Alden Chesney, MD, FRCPC, David Good, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC

Blood (2010) 116 (21): 1357.

https://doi.org/10.1182/blood.V116.21.1357.1357

Published: 2010

Journal Articles

Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.

Matthew C. Cheung, MD, Neil L. Berinstein, MD, Nancy Pennell, BSc, Lisa K. Hicks, MD, Kevin R. Imrie, MD, Eugenia Piliotis, MD, Violet Milliken, BSc, Marciano Reis, MD, Rena Buckstein, MD

Blood (2007) 110 (11): 1902.

https://doi.org/10.1182/blood.V110.11.1902.1902

Published: 2007

NARROW

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

An Index of SNPs in Immune Genes May Enhance the Prognostic Value of IPI in Patients with Aggressive Non-Hodgkin's Lymphoma

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only